Related Experiment Videos
[Medical treatment of cholesterol cholelithiasis using chemodeoxycholic acid in man]
Insights
Chenodeoxycholic acid effectively dissolves cholesterol gallstones in over half of patients, with higher doses and shorter treatment times yielding better results. Careful patient selection is key for successful treatment outcomes.
Area of Science:
- Hepatology and Gastroenterology
- Pharmacology and Therapeutics
Context:
- Cholesterol gallstones represent a significant clinical challenge.
- Chenodeoxycholic acid (CDCA) has been investigated for gallstone dissolution therapy.
Purpose:
- To report the efficacy and safety of chenodeoxycholic acid in a large cohort of patients with cholesterol gallstones.
- To compare treatment outcomes based on dosage, stone characteristics, and patient factors.
Summary:
- A trial involving 400 patients with cholesterol gallstones evaluated chenodeoxycholic acid treatment.
- Higher CDCA doses (12-15 mg/kg/day) resulted in higher dissolution rates (64%) and shorter treatment times (8 months) compared to lower doses (<12 mg/kg/day).
- Microcalculi showed the highest sensitivity to treatment (65% success).
Impact:
- Treatment duration was influenced by lithiasis duration and overweight status.
- Rigorous liver and intestinal function monitoring confirmed CDCA's non-hepatotoxic and non-enterotoxic profile.
- No serious adverse events were reported, highlighting the treatment's safety profile.
Abstract:
The results of a tiral using chenodeoxycholic acid in 400 patients with cholesterol gallstones are reported. The "qualifying points" of such treatment are compared with the literature data in clinical and laboratory terms. 54% of 300 in clinical and laboratory terms. 54% of 300 patients who received less than 12 mg/kg/day achieved dissolution in a mean time of 11 months, while 64% of the remainder (12-15 mg/kg/day) did so in an average of 8 months. Microcalculi proved most sensitive to treatment (65% of positive results). Lithiasis over 5 years standing and over-weight (10% over the ideal figure) were factors that imposed more protracted treatment. Careful selection of candidates was proved important by the results of quarterly liver and intestine performance examinations. These were more extensive and more clearly aimed than those proposed by other workers. They showed that the acid is neither hepato nor enterotoxic. Indeed, no serious side-effects were noted.